Qianming Du

Dr. Qianming Du


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
CLChao Liu
Chao Liu
ZYZhaoying Yao
Zhaoying Yao
JWJianing Wang
Jianing Wang
WZWen Zhang
Wen Zhang
YYYan Yang
Yan Yang
QDQianming Du
Qianming Du

14 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CZChunxue Zhang
Chunxue Zhang
YFYuxiang Fei
Yuxiang Fei
HWHui Wang
Hui Wang
SHSheng Hu
Sheng Hu
CLChao Liu
Chao Liu
QDQianming Du
Qianming Du
Cancer immunotherapy has opened a new landscape in cancer treatment, however, the poor specificity and resistance of most targeted therapeutics have limited their therapeutic efficacy. In recent years, the role of CAFs in immune regulation has been increasingly noted as more evidence has been uncovered regarding the link between cancer-associated fibroblasts (CAFs) and the evolutionary process of tumor progression. CAFs interact with immune cells to shape the tumor immune microenvironment (TIME) that favors malignant tumor progression, a crosstalk process that leads to the failure of cancer immunotherapies. In this review, we outline recent advances in the immunosuppressive function of CAFs, highlight the mechanisms of CAFs-immune cell interactions, and discuss current CAF-targeted therapeutic strategies for future study.

22 April 2023 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
XSXiaofan Sun
Xiaofan Sun
LZLisha Zhou
Lisha Zhou
YWYi Wang
Yi Wang
GDGuoliang Deng
Guoliang Deng
XCXinran Cao
Xinran Cao
Yang SunYang Sun
Yang Sun
Colorectal tumors often create an immunosuppressive microenvironment that prevents them from responding to immunotherapy. Cannabidiol (CBD) is a non-psychoactive natural active ingredient from the cannabis plant that has various pharmacological effects, including neuroprotective, antiemetic, anti-inflammatory, and antineoplastic activities. This study aimed to elucidate the specific anticancer mechanism of CBD by single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) technologies. Here, we report that CBD inhibits colorectal cancer progression by modulating the suppressive tumor microenvironment (TME). Our single-cell transcriptome and ATAC sequencing results showed that CBD suppressed M2-like macrophages and promoted M1-like macrophages in tumors both in strength and quantity. Furthermore, CBD significantly enhanced the interaction between M1-like macrophages and tumor cells and restored the intrinsic anti-tumor properties of macrophages, thereby preventing tumor progression. Mechanistically, CBD altered the metabolic pattern of macrophages and related anti-tumor signaling pathways. We found that CBD inhibited the alternative activation of macrophages and shifted the metabolic process from oxidative phosphorylation and fatty acid oxidation to glycolysis by inhibiting the phosphatidylinositol 3-kinase-protein kinase B signaling pathway and related downstream target genes. Furthermore, CBD-mediated macrophage plasticity enhanced the response to anti-programmed cell death protein-1 (PD-1) immunotherapy in xenografted mice. Taken together, we provide new insights into the anti-tumor effects of CBD.

1 February 2020 in Cancer Letters
Verified
Journal Article
Closed access
CLChao Liu
Chao Liu
YZYan Zhao
Yan Zhao
JWJianing Wang
Jianing Wang
YYYan Yang
Yan Yang
YZYan Zhang
Yan Zhang
QDQianming Du
Qianming Du

4 August 2021 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
YCYi Chen
Yi Chen
ZJZhaohui Jiang
Zhaohui Jiang
JXJinzhuan Xu
Jinzhuan Xu
JZJiyuan Zhang
Jiyuan Zhang
RSRunbin Sun
Runbin Sun
JPJianqing Peng
Jianqing Peng
Background: The combination of berberine (BER) and curcumin (CUR) has been verified with ameliorative effects on non-alcohol fatty liver disease (NAFLD). However, discrepant bioavailability and biodistribution of BER and CUR remained an obstacle to achieve synergistic effects. Multilayer nanovesicles have great potential for the protection and oral delivery of drug combinations. Therein lies bile salts inserted liposomes, named as bilosomes, that possesses long residence time in the gastrointestinal tract (GIT) and permeability across the small intestine. Diethylaminoethyl dextran (DEAE-DEX) is generally used as an outside layer on the nanovesicles to increase the mucinous stability and promote oral absorption. Herein, we developed a DEAE-DEX-coated bilosome with BER and CUR encapsulated (DEAE-DEX@LSDBC) for the treatment of NAFLD. Results: DEAE-DEX@LSDBC with 150 nm size exhibited enhanced permeation across mucus and Caco-2 monolayer. In vivo pharmacokinetics study demonstrated that DEAE-DEX@LSDBC profoundly prolonged the circulation time and improved the oral absorption of both BER and CUR. Intriguingly, synchronized biodistribution of BER and CUR and highest biodistribution at liver was achieved by DEAE-DEX@LSDBC, which contributed to the optimal ameliorative effects on NAFLD. It was further verified to be mainly mediated by anti-oxidation and anti-inflammation related pathways Conclusion: DEAE-DEX coated bilosome displayed promoted oral absorption, prolonged circulation and synchronized biodistribution of BER and CUR, leading to improved ameliorative effects on NAFLD in mice, which provided a promising strategy for oral administration of drug combinations. Graphic

1 June 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
JPJianqing Peng
Jianqing Peng
JZJia Zhou
Jia Zhou
RSRunbin Sun
Runbin Sun
YCYan Chen
Yan Chen
DPDi Pan
Di Pan
QDQianming Du
Qianming Du